Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Diagnosis of a myelodysplastic syndrome~* Refractory anemia (RA)~* RA with ringed sideroblasts~* RA with excess blasts (RAEB). RAEB patients must have a bone marrow blast count of less than 20% and less than 5% blast forms on peripheral blood~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3~* Platelet count greater than 30,000/mm\^3 (without platelet transfusions)~* Hematocrit less than 30% (pretransfusion)~* Bilirubin less than 3 mg/dL~* Blood urea nitrogen (BUN) less than 40 mg/dL or Creatinine less than 2.0 mg/dL~* Prior epoetin alfa allowed provided dosage was less than 30,000 units per week for less than 1 month duration~* At least 1 month since prior erythropoietin~* At least 2 months since prior recombinant growth factor~* At least 2 months since prior chemotherapy for other malignancy or autoimmune disease~* At least 2 weeks since prior androgen or steroids for treatment of myelodysplastic syndromes~Exclusion Criteria:~* RAEB in transformation~* Chronic myelomonocytic leukemia~* Splenomegaly greater than 6 cm below the left costal margin or greater than 3 times normal size~* Uncontrolled hypertension~* Sensitivity to E. coli-derived proteins~* Sensitivity to epoetin alfa or any of its components (e.g., human albumin)~* Documented iron deficiency. If marrow iron stain is not available, the transferrin saturation must be greater than 20% or ferritin greater than 100 ng/dL~* Active infection or bleeding~* Other uncontrolled malignancy~* Pregnant or nursing. Fertile patients must use effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive Care (Type: ACTIVE_COMPARATOR): Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of \>= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
- Erythropoietin (Type: EXPERIMENTAL): Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.

Based on this trial design, predict the completion outcome and termination type (if applicable).